Skip to main content

Advertisement

SpringerLink
Log in

Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

Several factors are known to be significantly associated with a low completion rate of 1-year adjuvant S-1 monotherapy for gastric cancer. The present study investigated whether or not the specialties of physicians conducting adjuvant S-1 monotherapy affect the completion rate.

Methods

A total of 437 patients who underwent curative gastrectomy followed by adjuvant S-1 monotherapy for pathological stage II or III gastric cancer between 2008 and 2013 were retrospectively analyzed. Factors affecting completion of adjuvant S-1 monotherapy, including the physicians (medical oncologists or surgeons) administering S-1, were evaluated by a multivariate analysis. The relationship between patient factors and physicians was analyzed regarding the cumulative incidence of discontinuation. The number of times the dose was reduced, the schedule changed, or administration was suspended or delayed in patients completing adjuvant S-1 monotherapy was also counted.

Results

The multivariate analysis showed that old age (≥ 65 years old), excess body weight loss (≥ 15%), and surgeons were independently associated with discontinuation. In older patients, the cumulative incidence of discontinuation by medical oncologists was significantly lower than that by surgeons. Medical oncologists ensured that older patients continued S-1 by frequent suspension or a delay in each course.

Conclusions

Medical oncologists may facilitate completion of adjuvant S-1 monotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, ACTS-GC Group, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  CAS  Google Scholar 

  2. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.

    Article  CAS  Google Scholar 

  3. Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304.

    Article  CAS  Google Scholar 

  4. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.

    Article  CAS  Google Scholar 

  5. Sakuramoto S, Kikuchi S, Watanabe M. Efficacy of S-1 (oral fluoropyrimidine) for gastric cancer. Med Frontl (Saishin Igaku). 2009;64:1075–80 (in Japanese).

    Google Scholar 

  6. Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:208–16.

    Article  Google Scholar 

  7. Yamashita K, Kurokawa Y, Yamamoto K, Hirota M, Kawabata R, Mikami J, et al. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol. 2017;24:2639–45.

    Article  Google Scholar 

  8. Kawazoe H, Shimasaki M, Ueno M, Sumikawa S, Takatori S, Namba H, et al. Risk factors for discontinuation of S-1 adjuvant chemotherapy for gastric cancer. J Cancer. 2015;6:464–9.

    Article  CAS  Google Scholar 

  9. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, et al. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastr Cancer. 2013;16:133–9.

    Article  CAS  Google Scholar 

  10. Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013;20:2000–6.

    Article  Google Scholar 

  11. Min JS, Lee CM, Choi SI, Seo KW, Park DJ, Baik YH, et al. Who can perform adjuvant chemotherapy treatment for gastric cancer? A multicenter retrospective overview of the current status in Korea. J Gastric Cancer. 2018;18:264–73.

    Article  Google Scholar 

  12. Japanese Classification of Gastric Carcinoma. 3rd English edition, Japanese Gastric Cancer Association Gastric Cancer. 2011;14:101–12.

  13. Tsujimoto H, Horiguchi H, Hiraki S, Yaguchi Y, Takahata R, Kumano I, et al. Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer. Oncol Lett. 2012;4:1135–9.

    Article  CAS  Google Scholar 

Download references

Funding

There are no sources of financial support to report.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Yosuke Kano, Manabu Ohashi, Satoshi Ida, Koshi Kumagai, Takeshi Sano & Souya Nunobe

  2. Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Kanagawa, Japan

    Naoki Hiki

  3. Department of Gastroenterological Medicine, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

    Daisuke Takahari, Keisho Chin & Kensei Yamaguchi

Authors
  1. Yosuke Kano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manabu Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoki Hiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Takahari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keisho Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kensei Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Ida
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Koshi Kumagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takeshi Sano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Souya Nunobe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manabu Ohashi.

Ethics declarations

Conflict of interest

Takeshi Sano received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, MSD and Eli Lilly; Kensei Yamaguchi received honoraria from Takeda Pharmaceutical Company Limited, Bayer, Daiichi-Sankyo, Sanofi, Dainippon-Sumitomo, MSD and Gilead and received research finding from Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Bristol-Myers Squibb, Yakult and Chugai Pharmaceutical; Daisuke Takahari received honoraria from Eli Lilly, Brustol-Myers Squibb, Yakult and Chugai Pharmaceutical, and received research finding from Taiho Pharmaceutical and Ono Pharmaceutical.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kano, Y., Ohashi, M., Hiki, N. et al. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists. Surg Today 50, 1197–1205 (2020). https://doi.org/10.1007/s00595-020-01995-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-020-01995-8

Keywords

Search

Navigation